Patents by Inventor Wenbo XIAO

Wenbo XIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240146502
    Abstract: A clock data recovery circuit and a clock data recovery method are provided. The clock data recovery circuit includes a time delay loop (100), a frequency locking loop (200) and a deserializer (300). The time delay loop (100) is configured to delay input data according to a phase of a clock signal to realize phase alignment; the frequency locking loop (200) is connected to the time delay loop (100), and is configured to adjust a frequency of the clock signal according to the delayed input data to make the frequency of the clock signal be consistent with a frequency of the input data; and the deserializer (300) is respectively connected to the time delay loop (100) and the frequency locking loop (200), and is configured to deserialize the input data according to the clock signal.
    Type: Application
    Filed: November 15, 2021
    Publication date: May 2, 2024
    Inventors: Quan PAN, Wenbo XIAO, Qiwei HUANG, Junyi YANG, Xuewei DING, Yingli HAO
  • Publication number: 20240145321
    Abstract: A substrate integrated with passive devices and a manufacturing method thereof are provided.
    Type: Application
    Filed: April 23, 2021
    Publication date: May 2, 2024
    Inventors: Chuncheng CHE, Feng LIU, Yuelei XIAO, Yue LI, Guochen DU, Xue CAO, Yifan WU, Wenbo CHANG
  • Publication number: 20240097617
    Abstract: A method for installing a maximum power point tracking (MPPT) controller is provided. The method includes acquiring an occlusion area proportion of a photovoltaic string in a photovoltaic system, optimizing the occlusion area proportion to generate a target occlusion area proportion, determining a target position from the photovoltaic string according to the target occlusion area proportion, and installing the MPPT controller at the target position.
    Type: Application
    Filed: June 23, 2022
    Publication date: March 21, 2024
    Inventors: Lizhen Luo, Wenbo Peng, Ping Xiao, Dongming Zhao, Xiaolei Li, Xiangrui Yu, Wenzhe Zhu, Hu Gao
  • Patent number: 11578074
    Abstract: A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: February 14, 2023
    Assignee: Shanghai Pharmaceuticals Holding Cd., Ltd.
    Inventors: Guangxin Xia, Di Li, Jing Zhang, Lingjun Duan, Hongjian Zuo, Wenbo Xiao, Jia Xu, Yanjun Liu
  • Publication number: 20200190091
    Abstract: A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target.
    Type: Application
    Filed: August 31, 2018
    Publication date: June 18, 2020
    Inventors: Guangxin XIA, Di LI, Jing ZHANG, Lingjun DUAN, Hongjian ZUO, Wenbo XIAO, Jia XU, Yanjun LIU